The German chemicals specialist announces €35 million expansion of its contract development and manufacturing capabilities for advanced injectables
Automated, custom-designed filling line for complex injectable products at Evonik Birmingham Laboratories
Evonik has announced a €35 million expansion of its contract development and manufacturing capabilities in North America to meet growing demand for controlled release injectable formulations. The expansion of the US and Canadian facilities, which includes the installation of a new filling line, production facilities and analytical labs, will create more than 50 jobs.
The investment plan includes the Installation of automated vial filling line for advanced injectables, and the construction of a new RESOMER production building at Evonik Birmingham Laboratories in Alabama, US.
In addition, Evonik Vancouver Laboratories in Canada will double in size to meet growing demand for its liposomal formulation development and manufacturing services.
“Evonik is a global strategic partner to pharmaceutical companies seeking enabling solutions for polymer and liposome-based dosage forms,” said Don Enns, Global Head of Drug Delivery for the Evonik Health Care Business Line.”
“By increasing the production capacity of our RESOMER functional excipients and expanding our contract development and production services, we can further help customers transform their APIs into high-performance parenteral medicines.”
Evonik Birmingham Laboratories (BHM) is a global centre of excellence for biomaterials and polymer-based injectable dosage forms.
To further expand its range of parenteral drug development and manufacturing services, Evonik has installed an automated, custom-designed filling line for complex injectable products.
Supplied by Bausch + Stroebel and scheduled to be fully operational later this year, the modular VarioSys line will support the liquid, lyophilised or powder-filling of drugs in vial sizes of up to 50mL to be used in clinical or commercial applications.
Evonik is also constructing a new 2,900 square metre building at its BHM site that will significantly expand the global production capacity of its RESOMER portfolio of bioresorbable polymers. The new building, which is scheduled to be commissioned later this year, will strengthen Evonik’s technological and supply leadership for bioresorbable polymers and provide customers with additional dual-source supply options.
Evonik Vancouver Laboratories to strengthen capabilities for lipid-based nanoparticles
In 2016, Evonik acquired Transferra Nanosciences Inc., a CDMO specialising in the development of lipid nanoparticle-based parenteral drugs. It is now named Evonik Vancouver Laboratories.
To help meet growing demand for its advanced CDMO services, Evonik is upgrading the existing facility and adding a second adjacent building that will more than double the total size of its Vancouver site to 4,300 sq m.
The investments, which include the upgrade of GMP manufacturing facilities and the expansion of laboratories and scale-up services, will support new and existing customer programmes.
Headquartered in Germany, Evonik is deemed one of the world leaders in speciality chemicals. The company is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.